Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $67,650.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 2,255 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now owns 124,421 shares of the company’s stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Collegium Pharmaceutical Stock Up 0.3 %

Shares of NASDAQ COLL opened at $29.93 on Friday. The business’s fifty day moving average price is $30.75 and its 200-day moving average price is $32.77. The stock has a market capitalization of $942.38 million, a PE ratio of 12.90 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth about $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Collegium Pharmaceutical by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock valued at $1,902,000 after acquiring an additional 7,063 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $822,000. Vident Advisory LLC raised its holdings in shares of Collegium Pharmaceutical by 27.8% in the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock valued at $484,000 after acquiring an additional 3,672 shares in the last quarter. Finally, Virtus Fund Advisers LLC raised its holdings in shares of Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 565 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on COLL. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.